Narrative Update on Bio-Techne
Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations.
What's in the News
- Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens. The collaboration aims to extend current 2D multiomic spatial tools into thicker, intact samples (Key Developments).
- Bio-Techne reported an expanded launch and first shipment of its next generation Leo System. The system now adds dual channel fluorescence detection to existing chemiluminescence, allowing multiplexing options and processing of up to 100 capillaries in roughly three hours (Key Developments).
- The company repurchased 500,000 shares for US$24.01m between July 1, 2025 and September 30, 2025, bringing total buybacks under the May 6, 2025 program to 2,443,140 shares for US$124.06m, or 1.56% of shares (Key Developments).
- Bio-Techne and Nucleai are presenting data from the SECOMBIT clinical trial at the 2025 SITC meeting, using the COMET platform and a 28 plex mIF panel with AI based multimodal biomarker analysis to study immune cell interactions in metastatic melanoma (Key Developments).
- Bio-Techne launched the ProximityScope assay for use with Leica Biosystems' BOND RX platform, providing subcellular visualization of protein protein interactions and integration with ACD's RNAscope Multiomic LS kit for combined RNA and protein detection on the same tissue section (Key Developments).
Valuation Changes
- Fair Value Estimate was nudged higher to US$70.00 per share from about US$69.17.
- The discount rate was adjusted slightly to 7.82% from about 7.84%.
- Revenue growth is now modeled at roughly 5.94% compared with about 6.02% previously.
- The net profit margin was kept effectively flat at about 18.94%.
- Future P/E is set at about 47.73x compared with roughly 47.06x in the prior view.
Have other thoughts on Bio-Techne?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.